Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer
AbstractWe have previously demonstrated a significant correlative relationship betweenPTEN deletion andERG rearrangement, both in the development of clinically localized prostate cancers and metastases. Herein, we evaluate the cooperative role of ERG and PTEN in oncological outcomes after radical prostatectomy for clinically localized prostate cancer. We evaluatedERG andPTEN status using three previously described cohorts. The first cohort included 235 clinically localized prostate cancer cases represented on tissue microarrays (TMA), evaluated using previously validated FISH assays forERG andPTEN. The second cohort includ...
Source: Medical Oncology - October 5, 2018 Category: Cancer & Oncology Source Type: research

Volumetric modulated arc therapy (VMAT) in the treatment of esophageal cancer patients
In conclusion, VMAT proved to be a feasible, safe, and effective strategy to deliver definitive or pre-operative radiation in locally advanced esopha geal cancer patients. (Source: Medical Oncology)
Source: Medical Oncology - October 4, 2018 Category: Cancer & Oncology Source Type: research

The use of radiofrequency ablation in pancreatic cancer in the midst of the dawn of immuno-oncology
AbstractDespite significant improvement in treatment, the prognosis of pancreatic ductal adenocarcinoma remains poor as the biology of the tumour affects survival even when a radical resection has been performed. Pancreatic cancer remains resistant to currently available chemotherapeutic options. Recently, immunotherapy has achieved significant results in certain types of cancer. However, for pancreatic cancer, results were not initially encouraging as pancreatic cancer microenvironment is highly immunosuppressive. Radiofrequency ablation is currently used as treatment option especially for liver cancer with significant re...
Source: Medical Oncology - October 4, 2018 Category: Cancer & Oncology Source Type: research

Volumetric modulated arc therapy (VMAT) in the treatment of esophageal cancer patients
In conclusion, VMAT proved to be a feasible, safe, and effective strategy to deliver definitive or pre-operative radiation in locally advanced esopha geal cancer patients. (Source: Medical Oncology)
Source: Medical Oncology - October 4, 2018 Category: Cancer & Oncology Source Type: research

The use of radiofrequency ablation in pancreatic cancer in the midst of the dawn of immuno-oncology
AbstractDespite significant improvement in treatment, the prognosis of pancreatic ductal adenocarcinoma remains poor as the biology of the tumour affects survival even when a radical resection has been performed. Pancreatic cancer remains resistant to currently available chemotherapeutic options. Recently, immunotherapy has achieved significant results in certain types of cancer. However, for pancreatic cancer, results were not initially encouraging as pancreatic cancer microenvironment is highly immunosuppressive. Radiofrequency ablation is currently used as treatment option especially for liver cancer with significant re...
Source: Medical Oncology - October 4, 2018 Category: Cancer & Oncology Source Type: research

Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues
AbstractBreast cancers with amplification and overexpression of human epithelial growth factor receptor 2 (HER2) are associated with poor prognosis, and targeted for anti-HER2 therapy. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are currently the recommended methods to asses HER2 overexpression/amplification. Droplet digital PCR (ddPCR), a highly accurate method to quantify DNA copy number, is potentially a robust alternative for HER2 diagnostics. In the FISH assay and most of previous ddPCR reports, chromosome 17 centromere (CEP17) has been used as the reference control to determine HER2/CEP17...
Source: Medical Oncology - October 3, 2018 Category: Cancer & Oncology Source Type: research

Hypofractionated stereotactic radiotherapy for oligometastatic patients: developing of a response predictive model
AbstractObjectivesTreatment of oligometastatic patients is a current challenge in radiation oncology. Aim of this study is to define a dose –response relationship for hypofractionated radiotherapy of oligometastases.MethodsRetrospective analysis of metastases treated by hypofractionated stereotactic radiotherapy was performed. Delivered dose was calculated both as biological effective dose (BED10), and as ratio between BED10 and the logarithm of metastasis volume (BED10 logVolume Ratio, BVR). Two dose –response models were defined by logistic regression. The fitted outcome was the Metastases Complete Response (...
Source: Medical Oncology - September 14, 2018 Category: Cancer & Oncology Source Type: research

Imaging of distant metastases of prostate cancer
AbstractThe detection of distant metastases at the initial diagnosis of prostate cancer (PCa) establishes the treatment approach and has a prognostic value, nevertheless it is not well established. Since proposed staging approaches often contradict each other, we aimed to compare the current imaging techniques for staging of advanced PCa, including future applications of the most innovative methods. Conventional imaging techniques, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) have been employed for metastatic staging (both N and M staging) of men with high-ris...
Source: Medical Oncology - September 14, 2018 Category: Cancer & Oncology Source Type: research

DNA methylation marker to estimate the breast cancer cell fraction in DNA samples
AbstractEstimation of the cancer cell fraction in breast cancer tissue is important for exclusion of samples unsuitable for multigene prognostic assays and a variety of molecular analyses for research. Here, we aimed to establish a breast cancer cell fraction marker based on DNA methylation. First, we screened genes unmethylated in non-cancerous mammary tissues and methylated in breast cancer tissues using microarray data from the TCGA database, and isolated 12 genes. Among them, four genes were selected as candidate marker genes without a high incidence of copy number alterations and with broad coverage across patients. B...
Source: Medical Oncology - September 14, 2018 Category: Cancer & Oncology Source Type: research

Imaging of distant metastases of prostate cancer
AbstractThe detection of distant metastases at the initial diagnosis of prostate cancer (PCa) establishes the treatment approach and has a prognostic value, nevertheless it is not well established. Since proposed staging approaches often contradict each other, we aimed to compare the current imaging techniques for staging of advanced PCa, including future applications of the most innovative methods. Conventional imaging techniques, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) have been employed for metastatic staging (both N and M staging) of men with high-ris...
Source: Medical Oncology - September 14, 2018 Category: Cancer & Oncology Source Type: research

DNA methylation marker to estimate the breast cancer cell fraction in DNA samples
AbstractEstimation of the cancer cell fraction in breast cancer tissue is important for exclusion of samples unsuitable for multigene prognostic assays and a variety of molecular analyses for research. Here, we aimed to establish a breast cancer cell fraction marker based on DNA methylation. First, we screened genes unmethylated in non-cancerous mammary tissues and methylated in breast cancer tissues using microarray data from the TCGA database, and isolated 12 genes. Among them, four genes were selected as candidate marker genes without a high incidence of copy number alterations and with broad coverage across patients. B...
Source: Medical Oncology - September 14, 2018 Category: Cancer & Oncology Source Type: research

Hypofractionated stereotactic radiotherapy for oligometastatic patients: developing of a response predictive model
AbstractObjectivesTreatment of oligometastatic patients is a current challenge in radiation oncology. Aim of this study is to define a dose –response relationship for hypofractionated radiotherapy of oligometastases.MethodsRetrospective analysis of metastases treated by hypofractionated stereotactic radiotherapy was performed. Delivered dose was calculated both as biological effective dose (BED10), and as ratio between BED10 and the logarithm of metastasis volume (BED10 logVolume Ratio, BVR). Two dose –response models were defined by logistic regression. The fitted outcome was the Metastases Complete Response (...
Source: Medical Oncology - September 14, 2018 Category: Cancer & Oncology Source Type: research

Genetic variations using whole-exome sequencing might predict response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer
AbstractA good pathologic response to neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) is associated with a better prognosis. However, there is no effective method to predict CRT response in LARC patients. Therefore, this study used whole-exome sequencing (WES) to identify novel biomarker predicting CRT benefit in LARC. Two independent tumor tissue sets were used to evaluate the genetic differences between the good CRT response group (15 patients achieved a pathologic complete response (pCR)) and the poor CRT response group (15 patients with pathologic stage III). After applying WES to the disco...
Source: Medical Oncology - September 11, 2018 Category: Cancer & Oncology Source Type: research

Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis
AbstractChimeric antigen receptor (CAR) T-cell therapy has shown promise for relapsed/refractory malignancies. Many patients have undergone prior hematopoietic stem cell transplant (HSCT), yet effects of transplant status on CAR T-cell therapy efficacy and safety have not been reported. The purpose of the study is to systematically evaluate the likelihood of achieving optimum response, severe cytokine release syndrome (sCRS), and neurotoxicity in the context of CAR T-cell therapy for HSCT-na ïve patients versus those with prior HSCT. Trials were identified in ClinicalTrials.gov, Cochrane Library, and PubMed, and throu...
Source: Medical Oncology - September 11, 2018 Category: Cancer & Oncology Source Type: research

The critical role of comorbidities and polypharmacy in lower risk myelodysplastic patients: is there any difference between countries?
(Source: Medical Oncology)
Source: Medical Oncology - September 11, 2018 Category: Cancer & Oncology Source Type: research

Genetic variations using whole-exome sequencing might predict response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer
AbstractA good pathologic response to neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) is associated with a better prognosis. However, there is no effective method to predict CRT response in LARC patients. Therefore, this study used whole-exome sequencing (WES) to identify novel biomarker predicting CRT benefit in LARC. Two independent tumor tissue sets were used to evaluate the genetic differences between the good CRT response group (15 patients achieved a pathologic complete response (pCR)) and the poor CRT response group (15 patients with pathologic stage III). After applying WES to the disco...
Source: Medical Oncology - September 11, 2018 Category: Cancer & Oncology Source Type: research

Effect of transplant status in CD19-targeted CAR T-cell therapy: a systematic review and meta-analysis
AbstractChimeric antigen receptor (CAR) T-cell therapy has shown promise for relapsed/refractory malignancies. Many patients have undergone prior hematopoietic stem cell transplant (HSCT), yet effects of transplant status on CAR T-cell therapy efficacy and safety have not been reported. The purpose of the study is to systematically evaluate the likelihood of achieving optimum response, severe cytokine release syndrome (sCRS), and neurotoxicity in the context of CAR T-cell therapy for HSCT-na ïve patients versus those with prior HSCT. Trials were identified in ClinicalTrials.gov, Cochrane Library, and PubMed, and throu...
Source: Medical Oncology - September 11, 2018 Category: Cancer & Oncology Source Type: research

The critical role of comorbidities and polypharmacy in lower risk myelodysplastic patients: is there any difference between countries?
(Source: Medical Oncology)
Source: Medical Oncology - September 11, 2018 Category: Cancer & Oncology Source Type: research

Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis
AbstractTreatment with a tyrosine kinase inhibitor (TKI) is the standard of care for patients with chronic myeloid leukemia (CML). The new-generation TKIs, nilotinib and dasatinib, are found to have deeper and faster treatment response rates compared to imatinib in the first-line setting. However, a direct comparison between nilotinib and dasatinib has never been reported previously. Our study aims to compare the outcomes and molecular responses achieved following the first-line use of these two agents in patients with CML-CP. The database of the CML Cooperative Study Group was reviewed and patients with CML in the chronic...
Source: Medical Oncology - September 7, 2018 Category: Cancer & Oncology Source Type: research

Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis
AbstractAprepitant prevents chemotherapy-induced nausea and vomiting (CINV) in carboplatin-containing chemotherapy. However, it is unknown whether aprepitant salvage therapy after the development of emesis is as effective as adding prophylactic aprepitant to doublet therapy with dexamethasone and a 5-HT3 receptor antagonist from the first cycle of chemotherapy. To compare the antiemetic efficacy of aprepitant between salvage and prophylactic administration in the second cycle of carboplatin-containing chemotherapy, twenty-two NSCLC patients who developed CINV in the first cycle of carboplatin-containing therapy without apr...
Source: Medical Oncology - September 5, 2018 Category: Cancer & Oncology Source Type: research

Human papillomavirus and colorectal cancer
AbstractThe involvement of human papillomavirus in carcinogenesis of colorectal cancer is a contentious issue. The presented meta-analysis was performed to systematize the currently available research results on the matter. The analysis was based on the data from 19 studies to assess the association of HPV infection with colorectal cancer. According to the obtained data, researchers determined the statistically significant level of HPV infection in tumor tissue of CRC and the resulting relative risk of developing CRC with HPV infection to be RR (95% CI)  = 2.97 (1.42–6.22) withp = 0.0039. ...
Source: Medical Oncology - September 5, 2018 Category: Cancer & Oncology Source Type: research

Overall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a  cross-sectional study
AbstractPrognostic stratification in acute myeloid leukemia (AML) relies, mostly, on cytogenetics and molecular features of leukemic blasts. The LeukemiaNet prognostic scoring system has been proposed as a standardized way of evaluating prognosis in AML.  We have analysed outcomes in 65 AML cases (median age of 54 years, range 18–82) treated at five hematology centers in Brazil stritified according to the European Leukemia Net (ELN) recommendations for cytogenetic and molecular analysis. We classified patients as favorable (N = 13), intermediate-1 (N = 25), interme...
Source: Medical Oncology - September 5, 2018 Category: Cancer & Oncology Source Type: research

Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma
ConclusionSEF is an aggressive sarcoma subtype with a poor outcome and with limited responsiveness to conventional chemotherapy. Patients with this subtype should be considered for participation in clinical trials with novel agents. Further investigation into the biology of this rare disease is required to improve outcomes. (Source: Medical Oncology)
Source: Medical Oncology - September 5, 2018 Category: Cancer & Oncology Source Type: research

Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis
AbstractAprepitant prevents chemotherapy-induced nausea and vomiting (CINV) in carboplatin-containing chemotherapy. However, it is unknown whether aprepitant salvage therapy after the development of emesis is as effective as adding prophylactic aprepitant to doublet therapy with dexamethasone and a 5-HT3 receptor antagonist from the first cycle of chemotherapy. To compare the antiemetic efficacy of aprepitant between salvage and prophylactic administration in the second cycle of carboplatin-containing chemotherapy, twenty-two NSCLC patients who developed CINV in the first cycle of carboplatin-containing therapy without apr...
Source: Medical Oncology - September 5, 2018 Category: Cancer & Oncology Source Type: research

Human papillomavirus and colorectal cancer
AbstractThe involvement of human papillomavirus in carcinogenesis of colorectal cancer is a contentious issue. The presented meta-analysis was performed to systematize the currently available research results on the matter. The analysis was based on the data from 19 studies to assess the association of HPV infection with colorectal cancer. According to the obtained data, researchers determined the statistically significant level of HPV infection in tumor tissue of CRC and the resulting relative risk of developing CRC with HPV infection to be RR (95% CI)  = 2.97 (1.42–6.22) withp = 0.0039. ...
Source: Medical Oncology - September 5, 2018 Category: Cancer & Oncology Source Type: research

Overall survival of Brazilian acute myeloid leukemia patients according to the European LeukemiaNet prognostic scoring system: a  cross-sectional study
AbstractPrognostic stratification in acute myeloid leukemia (AML) relies, mostly, on cytogenetics and molecular features of leukemic blasts. The LeukemiaNet prognostic scoring system has been proposed as a standardized way of evaluating prognosis in AML.  We have analysed outcomes in 65 AML cases (median age of 54 years, range 18–82) treated at five hematology centers in Brazil stritified according to the European Leukemia Net (ELN) recommendations for cytogenetic and molecular analysis. We classified patients as favorable (N = 13), intermediate-1 (N = 25), interme...
Source: Medical Oncology - September 5, 2018 Category: Cancer & Oncology Source Type: research

Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma
ConclusionSEF is an aggressive sarcoma subtype with a poor outcome and with limited responsiveness to conventional chemotherapy. Patients with this subtype should be considered for participation in clinical trials with novel agents. Further investigation into the biology of this rare disease is required to improve outcomes. (Source: Medical Oncology)
Source: Medical Oncology - September 5, 2018 Category: Cancer & Oncology Source Type: research

Double-mutant myeloproliferative neoplasms
(Source: Medical Oncology)
Source: Medical Oncology - August 29, 2018 Category: Cancer & Oncology Source Type: research

Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study
AbstractThere are limited treatment modalities after high-grade gliomas recurrence. MGMT depletion modulated by dose-dense temozolomide (ddTMZ) remains a debated therapy for initial TMZ responders. Patients were selected retrospectively from our practice with diagnosis of high-grade gliomas (WHO grade III or IV), and were followed since the start of ddTMZ until death or change of therapy. Twenty-one patients were reviewed, with a median age of 47 (25 –61) years and a median of 5.8 (1.5–38.8) cycles of ddTMZ. The majority were males (71.4%). Sixty-six percent received 21 on/28 off ddTMZ schedule, 28.6% daily, an...
Source: Medical Oncology - August 28, 2018 Category: Cancer & Oncology Source Type: research

Primary leiomyosarcoma of the skin: a comprehensive review on diagnosis and treatment
This article is intended to provide an up to date and systematic overview on diagnosis, treatment, and surveillance of this rare entity to provide a framework for decision making and management for dermato-oncologists. We discuss novel treatment options for advanced disease such as targeted therapy with kinase inhibitors and immune checkpoint blockade which may improve the prognosis even in advanced stages of LMS. (Source: Medical Oncology)
Source: Medical Oncology - August 23, 2018 Category: Cancer & Oncology Source Type: research

Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy
AbstractThe best curative option for locally advanced (stages II –III) squamous-cell carcinomas of the anal canal (SCCAC) is concurrent chemo-radiotherapy delivering 36–45 Gy to the prophylactic planning target volume with an additional boost of 14–20 Gy to the gross tumor volume with or without a gap-period between these two sequences. Although 3-dimensi onal conformal radiotherapy led to suboptimal tumor coverage because of field junctions, this modality remains a standard of care. Recently, intensity-modulated radiotherapy (IMRT) techniques improved tumor coverage while decreasing doses deliv...
Source: Medical Oncology - August 20, 2018 Category: Cancer & Oncology Source Type: research

Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
AbstractThe outcome for patients with unresectable or metastatic soft tissue sarcoma remains poor with few treatment options. Synovial sarcoma is a rare type of sarcoma, predominantly affecting adolescents and young adults. Following failure of first-line anthracycline-based chemotherapy, several salvage options are available. We reviewed the safety and efficacy of gemcitabine/docetaxel chemotherapy in two tertiary oncology centres. We identified patients treated with gemcitabine/docetaxel between 2004 and 2016 in a UK and a US oncology centre using retrospective pharmacy and medical records. Treatment response, toxicity a...
Source: Medical Oncology - August 20, 2018 Category: Cancer & Oncology Source Type: research

Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma
This study included 154 patients treated with sunitinib as first-line systemic therapy for mRCC, consisting of 62, 47, and 45 receiving sunitinib based on a traditional schedule (TS, 4  weeks on and 2 weeks off) alone (TS group), alternative schedule (AS, 2 weeks on and 1 week off) alone (AS group), and TS followed by AS after the development of dose-limiting toxicities (TS-to-AS group), respectively. There were no significant differences in the major clinicopathological chara cteristics among these three groups. The progression-free survival in the TS group was significantly shorter than in the other t...
Source: Medical Oncology - August 20, 2018 Category: Cancer & Oncology Source Type: research

Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy
AbstractThe best curative option for locally advanced (stages II –III) squamous-cell carcinomas of the anal canal (SCCAC) is concurrent chemo-radiotherapy delivering 36–45 Gy to the prophylactic planning target volume with an additional boost of 14–20 Gy to the gross tumor volume with or without a gap-period between these two sequences. Although 3-dimensi onal conformal radiotherapy led to suboptimal tumor coverage because of field junctions, this modality remains a standard of care. Recently, intensity-modulated radiotherapy (IMRT) techniques improved tumor coverage while decreasing doses deliv...
Source: Medical Oncology - August 20, 2018 Category: Cancer & Oncology Source Type: research

Patient performance status and cancer immunotherapy efficacy: a meta-analysis
AbstractImmune checkpoint inhibitors (CKIs) are therapeutic weapons in several advanced malignancies. Performance status is a validated prognostic variable in cancer patients; it possibly affects the efficiency of the immune system. We performed a systematic review and meta-analysis to investigate the predictive role of PS toward treatment with CKIs in cancer patients. Following PRISMA guidelines, an electronic search from PubMed, The Cochrane Library and Embase was performed, from the inception of each database to May 31, 2018. Inclusion criteria were (1) randomized trials comparing CKI with standard therapy for the treat...
Source: Medical Oncology - August 20, 2018 Category: Cancer & Oncology Source Type: research

Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma
AbstractThe outcome for patients with unresectable or metastatic soft tissue sarcoma remains poor with few treatment options. Synovial sarcoma is a rare type of sarcoma, predominantly affecting adolescents and young adults. Following failure of first-line anthracycline-based chemotherapy, several salvage options are available. We reviewed the safety and efficacy of gemcitabine/docetaxel chemotherapy in two tertiary oncology centres. We identified patients treated with gemcitabine/docetaxel between 2004 and 2016 in a UK and a US oncology centre using retrospective pharmacy and medical records. Treatment response, toxicity a...
Source: Medical Oncology - August 20, 2018 Category: Cancer & Oncology Source Type: research

Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma
This study included 154 patients treated with sunitinib as first-line systemic therapy for mRCC, consisting of 62, 47, and 45 receiving sunitinib based on a traditional schedule (TS, 4  weeks on and 2 weeks off) alone (TS group), alternative schedule (AS, 2 weeks on and 1 week off) alone (AS group), and TS followed by AS after the development of dose-limiting toxicities (TS-to-AS group), respectively. There were no significant differences in the major clinicopathological chara cteristics among these three groups. The progression-free survival in the TS group was significantly shorter than in the other t...
Source: Medical Oncology - August 20, 2018 Category: Cancer & Oncology Source Type: research

Expression of Concern: Knockdown of eIF3d inhibits cell proliferation through G2/M phase arrest in non-small cell lung cancer
(Source: Medical Oncology)
Source: Medical Oncology - August 18, 2018 Category: Cancer & Oncology Source Type: research

Expression of concern: Short hairpin RNA (shRNA) of type 2 interleukin-1 receptor (IL1R2) inhibits the proliferation of human osteosarcoma U-2 OS cells
(Source: Medical Oncology)
Source: Medical Oncology - August 17, 2018 Category: Cancer & Oncology Source Type: research

Association of baseline patient characteristics with adjuvant chemotherapy toxicities in stage III colorectal cancer patients
AbstractToxicities can affect cancer patients ’ quality of life resulting in poor adherence to adjuvant chemotherapy (AC). While previous studies have explored the prevalence of toxicities following AC, few have examined the associations of baseline characteristics, such as age, sex, and performance status, with toxicity outcomes. In this stu dy, we reviewed a cohort of 371 colorectal cancer patients treated with adjuvant monotherapy (capecitabine ) or combination therapy (FOLFOX or CAPOX) within 12 weeks of curative resection, and determined the associations between baseline characteristics and toxicity outcome...
Source: Medical Oncology - August 16, 2018 Category: Cancer & Oncology Source Type: research

Reduced HBV cccDNA and HBsAg in HBV-associated hepatocellular carcinoma tissues
This study aimed to investigate relationships between serum HBsAg, intrahepatic HBsAg, and intrahepatic cccDNA in HBV-associated HCC. Intrahepatic HBsAg was determined by immunohistochemistry in matched non-cancerous and HCC tissues from 88 patients; 56 patients (63.64%) were serum HBsAg positive. In serum HBsAg-positive group, intrahepatic HBsAg was positive staining in 73.2% of non-cancerous tissues, but only in 10.7% of HCC tissues. Significant correlation between serum HBsAg and intrahepatic HBsAg was observed in non-cancerous tissues (p 
Source: Medical Oncology - August 16, 2018 Category: Cancer & Oncology Source Type: research

Sorafenib in patients with progressed and refractory bone tumors
AbstractPatients with metastatic, progressive, or recurrent bone tumors have a dismal outcome. Sorafenib has been proposed as an effective salvage regimen for some malignancies. Thus, we sought to evaluate this approach for young patients with relapsed or refractory bone tumors. Twelve patients with refractory bone tumors (two with Ewing sarcoma, two with chondrosarcoma, and eight with osteosarcoma) received salvage treatment with sorafenib. All patients had standard tumor imaging and laboratory evaluation. All toxicities were documented. At the time of the beginning of sorafenib treatment median age among 12 patients was ...
Source: Medical Oncology - August 16, 2018 Category: Cancer & Oncology Source Type: research

Pre-therapy CT scan showing peritoneal thickening from metastatic renal pelvis carcinoma patients
In conclusion. peritoneal thickening with clinical suspicion of peritoneal involvement can get indirect evidence from route of spread (liver or abdominal wall), GI complications (obstruction or bleeding) or response to chemotherapy (obvious decrease peritoneal thickening) from metastatic renal pelvis carcinoma patients. Pretherapy CT scan with peritoneal thickening should be alert that tumor has spread to the peritoneum. (Source: Medical Oncology)
Source: Medical Oncology - August 16, 2018 Category: Cancer & Oncology Source Type: research

Broccoli extract improves chemotherapeutic drug efficacy against head –neck squamous cell carcinomas
In conclusion, combi ning SF with low doses of CIS or 5-FU increased cytotoxicity against SCCHN cells, while having minimal effects on normal cells. (Source: Medical Oncology)
Source: Medical Oncology - August 4, 2018 Category: Cancer & Oncology Source Type: research

Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors
AbstractGastroenteropancreatic (GEP) neuroendocrine tumors (NETs) represent a heterogeneous group of tumors that is associated with an indolent course. Octreotide has a positive effect on disease stabilization in well-differentiated midgut NETs, but a meaningful survival analysis was not possible due to insufficient events. Higher doses of octreotide long-acting release (LAR) are often used in clinical practice for control of carcinoid symptoms and our objective was to determine if dose of octreotide correlates with survival. We reviewed all patients with advanced GEP NETs who initiated treatment with octreotide LAR betwee...
Source: Medical Oncology - August 4, 2018 Category: Cancer & Oncology Source Type: research